The price of LLY.US (LLY.US) best-selling diabetes and weight loss drugs will be reduced by more than 20% in Canada, effective December 29

The Zhitong Finance App learned that, according to reports, Lilly (LLY.US) will drastically cut the prices of its two best-selling diabetes and weight loss drugs — Mounjaro and Zepbound — in Canada by 20% or more. After the adjustment, based on the four-week dosage, the list price of these two drugs in the Canadian market will be reduced to 300 Canadian dollars (about 217 US dollars) for 2.5 mg and 5 mg; the price for the two higher specifications of 7.5 mg and 10 mg will drop to 420 Canadian dollars. The new prices will officially take effect on December 29th.

Eli Lilly did not immediately respond to requests for comment during non-working hours.

Earlier this month, Eli Lilly cut the price of the weight loss drug Zepbound in a single small bottle in the US to make it more affordable for American patients.

By Wednesday's close, the stock was down more than 1% to $1041.79.